Soumit Roy
Stock Analyst at Jones Trading
(0.60)
# 3,491
Out of 4,670 analysts
27
Total ratings
14.29%
Success rate
-11.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPIX ESSA Pharma | Downgrades: Hold | n/a | $1.83 | - | 1 | Nov 1, 2024 | |
| ELTX Elicio Therapeutics | Initiates: Buy | $9 | $4.93 | +82.56% | 1 | Oct 31, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $36 | $24.54 | +46.70% | 1 | Oct 31, 2024 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $17 | $9.59 | +77.27% | 1 | Oct 31, 2024 | |
| BEAM Beam Therapeutics | Initiates: Hold | n/a | $25.05 | - | 1 | Sep 17, 2024 | |
| EDIT Editas Medicine | Initiates: Buy | $13 | $2.44 | +432.79% | 1 | Sep 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $6 → $4 | $0.90 | +344.44% | 2 | Sep 11, 2024 | |
| INAB IN8bio | Downgrades: Hold | n/a | $0.32 | - | 3 | Aug 12, 2024 | |
| SAVA Cassava Sciences | Downgrades: Hold | n/a | $26.48 | - | 2 | Jul 1, 2024 | |
| CRVO CervoMed | Initiates: Buy | $70 | $9.60 | +629.17% | 1 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.58 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $12.54 | +107.34% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $50.31 | +39.14% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $20.10 | -50.25% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.55 | +296.95% | 1 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.95 | +843.30% | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.19 | +1,955.50% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.31 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.77 | +938.96% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $7.26 | +11,057.02% | 1 | Feb 24, 2021 |
ESSA Pharma
Nov 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.83
Upside: -
Elicio Therapeutics
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $4.93
Upside: +82.56%
Enliven Therapeutics
Oct 31, 2024
Initiates: Buy
Price Target: $36
Current: $24.54
Upside: +46.70%
ORIC Pharmaceuticals
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $9.59
Upside: +77.27%
Beam Therapeutics
Sep 17, 2024
Initiates: Hold
Price Target: n/a
Current: $25.05
Upside: -
Editas Medicine
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $2.44
Upside: +432.79%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.90
Upside: +344.44%
IN8bio
Aug 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.32
Upside: -
Cassava Sciences
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $26.48
Upside: -
CervoMed
May 29, 2024
Initiates: Buy
Price Target: $70
Current: $9.60
Upside: +629.17%
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.58
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $12.54
Upside: +107.34%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $50.31
Upside: +39.14%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $20.10
Upside: -50.25%
Aug 18, 2023
Initiates: Buy
Price Target: $26
Current: $6.55
Upside: +296.95%
May 24, 2023
Initiates: Buy
Price Target: $9
Current: $0.95
Upside: +843.30%
Apr 19, 2023
Initiates: Buy
Price Target: $4
Current: $0.19
Upside: +1,955.50%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.31
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $8
Current: $0.77
Upside: +938.96%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $7.26
Upside: +11,057.02%